A new delivery method for antagonist antibodies to reach their targets inside the fluid-filled kidney cyst lumens causing ADPKD.
Autosomal dominant polycystic kidney disease (ADPKD) is considered the most common and life threatening disease resulting from the modification of a single gene in the genome of the body. ADPKD is a slowly progressive disease of the kidneys with no cure or approved treatments available. ADPKD affects more than 600,000 people in the United States alone. By the age of 50, patients usually suffer from complete renal failure and have to resort directly to a kidney transplant or life-long kidney dialysis. Treatments are currently being researched around the world and biotech companies have been diligent in producing antagonistic antibodies to combat this disease. However, the classes of antibodies recently produced by biotech companies do not have the ability to permeate the cyst lumens in the kidney to reach their appropriate target for treatment. As a result these treatments are ineffective.
Researchers at the University of California, Santa Barbara have invented a new delivery method for antagonist antibodies to reach their targets inside the fluid-filled kidney cyst lumens causing ADPKD. This new delivery method incorporates a special class of antibodies that has the ability to travel from the patient’s circulatory system to the kidneys and penetrate through the epithelial cells of the cyst-lining and accumulate on the inside to act as inhibitors for growth factors. This delivery method can also be adapted to be used for the treatment of various other kidney diseases and problems such as chronic kidney failure. Another advantage to this new delivery method is the capability of reformatting other antibodies into this new specialized class of antibodies that then can be used for treatment of ADPKD and other kidney diseases.
· Ability to exclusively treat affected areas of the kidney
· Ability to reformat previously made antibodies to be used in this way
· Can be modified to treat other kidney diseases
· Treatment of autosomal dominant polycystic kidney disease (ADPKD)
· Antibody transport to affected areas of kidney
|United States Of America||Published Application||20170210793||07/27/2017||2014-336|
kidney disease, ADPKD, Autosomal dominant polycystic kidney disease, indpharma